Health Net, Inc. Provides Coverage for Biodesix’ VeriStrat Test
HealthNet now covers Biodesix' VeriStrat test
254 Results
HealthNet now covers Biodesix' VeriStrat test
GeneStrat blood-based mutation testing for advanced lung cancer offers significant advantages for patients and their treating physicians over standard tissue testing, which can delay treatment.
Biodesix raises follow-on series E financing
Biodesix recently added Biognosys' Proteomics to their capabiltites.
Biodesix named to Inc. 500|5000 Fastest-Growing Private Companies list
VeriStrat and Epidermal Growth Factor Receptor Mutation Status Study results presented at 16th World Conference on Lung Cancer
Biodesix data on proteomic and genomic blood-based assays presented at EORTC
Biodesix announced that the VeriStrat® test is now considered a medically necessary benefit by Aetna Corporation.
Biodesix CEO David Brunel will present a corporate overview on Deep Phenotyping, Machine Learning to Precision Medicine at the Leerink Partners Conference
Investigational blood test identifies patients with melanoma who are more likely to have improved survival on Nivolumab therapy.